1)) miRview® mets2 may be ordered only by physicians. 2)) Oncologists and pathologists are often faced with
a diagnostic dilemma when trying to identify the primary origin of a patient’s metastasis. 3)) The performance characteristics of this test were determined by Rosetta Genomics in accordance with the requirements of CLIA (Clinical Laboratory Improvement Amendments of 1988).
It has not been cleared or approved by the U.S. Food and Drug Administration. This test is intended to be used for clinical purposes and should not be considered to be for investigational or research use only. Decisions regarding care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient’s condition, including other tests.